title: A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells.
abstract: BACKGROUND
  Recombinant chimeric immune receptors (CIRs) with anti-CEA specificity can retarget grafted T-cells to CEA-expressing tumors in an HLA-independent manner. To reduce the immunogenicity of conventional CIR in humans, an attempt was made to generate a CIR encoded by all human genes.
  
  
  METHODS
  A single-chain variable fragmented (scFv) antibody gene was prepared from variable region genes of the C2-45 human mAb clone specific for CEA. The scFv gene was connected to a gene construct comprised of the cDNAs for the human CD8a hinge region, the human CD28 transmembrane and cytoplasmic domains, and the human CD3zeta intracellular domain. The resulting human CIR gene, designated L45scFv-CIR, was inserted into the pcDNA3.1 expression vector and transfected into human primary T-cells.
  
  
  RESULTS
  Flow cytometric analysis using allophycocyanin-labeled CEA demonstrated the expression of the L45scFv-CIR protein on the T-cells and its specific antigen binding activity.
  
  
  CONCLUSIONS
  This L45scFv-CIR gene, consisting of four human genes, may be a useful tool for eradication of CEA-expressing but HLA-downregulated tumor cells.
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. shiba-h@cis.fukuoka-u.ac.jp
authors.forename: Hirotomo
authors.initials: H
authors.lastname: Shibaguchi
authors.forename: Nai-Xiang
authors.initials: NX
authors.lastname: Luo
authors.forename: Motomu
authors.initials: M
authors.lastname: Kuroki
authors.forename: Jun
authors.initials: J
authors.lastname: Zhao
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
authors.forename: Ken
authors.initials: K
authors.lastname: Hachimine
authors.forename: Tetsushi
authors.initials: T
authors.lastname: Kinugasa
authors.forename: Masahide
authors.initials: M
authors.lastname: Kuroki
mesh_terms: D018106:CD28 Antigens / Q000235:genetics / Q000276:immunology; D017252:CD3 Complex / Q000235:genetics / Q000276:immunology; D016827:CD8 Antigens / Q000235:genetics / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000096:biosynthesis / Q000276:immunology*; D045744:Cell Line, Tumor; D000939:Epitopes; D006801:Humans; D011971:Receptors, Immunologic / Q000235:genetics / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D013274:Stomach Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology* / Q000502:physiology; D014162:Transfection
chemical_list: D018106:CD28 Antigens; D017252:CD3 Complex; C121704:CD3 antigen, zeta chain; D016827:CD8 Antigens; C431698:CD8alpha antigen; D002272:Carcinoembryonic Antigen; D000939:Epitopes; D011971:Receptors, Immunologic; D011993:Recombinant Fusion Proteins